Qiagen (QGEN) Tops Q1 EPS by 7c; Suspends Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
QIAGEN Reports Full Results for First Quarter of 2020
May 6, 2020 4:05 PM EDTQ1 2020 results: Net sales of $372.1 million (+7% actual, +9% CER vs. ~+2-3% CER outlook) Diluted EPS $0.17; adjusted EPS $0.34 ($0.34 CER vs. ~$0.28-0.29 CER outlook) Fully mobilized teams addressing COVID-19 pandemic testing demand, dramatically ramping up production of RNA extraction kits, QIAstat-Dx tests and components for third-party tests QIAGEN expects higher results for Q2 2020 based on trends to date and suspends outlook for full-year 2020
VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:... More
